ArticleCureus2026
Monoclonal Gammopathy as a Potential Cause of Pure Red Cell Aplasia: A Case Report and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pure red cell aplasia (PRCA) secondary to plasma cell dyscrasias has been previously reported; however, these cases are rare and often lack clinical details. Here, we report the case of a 44-year-old female patient presenting with progressive normocytic anemia in the setting of an IgG-kappa monoclonal gammopathy, without meeting the diagnostic criteria for multiple myeloma or any other hematological malignancy. Although the initial diagnostic workup for PRCA was inconclusive, and despite a transient response to erythropoiesis-stimulating agents, the condition progressed to severe, transfusion-dependent anemia. PRCA was eventually confirmed and proved refractory to conventional immunosuppressive therapy. Remarkably, plasma cell-directed therapy achieved almost instantaneous normalization of erythropoiesis and rapid paraprotein clearance. This clinical response suggests a pathogenetic role for the monoclonal immunoglobulin. While we were unable to demonstrate an in vitro inhibitory effect of the patient's serum on burst-forming unit-erythroid cultures, our observations, coupled with previously reported cases, support an antibody-mediated mechanism in the pathogenesis of this PRCA variant. We suggest that PRCA associated with monoclonal gammopathy may represent a rare, distinct clinical entity for which plasma cell-targeted therapy could be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.